To test the hypothesis, Kim et al. (42) conducted an exploratory phase II randomized clinical trial (RCT) to test secukinumab (IL-17A inhibitor) for mild-to-moderate psoriasis (NCT03131570). The gene discussed is IL17A; the disease is psoriasis.